After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib, last Monday, Revolution Medicines is not resting on its laurels. The Bay Area biotech spent several recent days in San Diego highlighting earlier data for its lead candidate and the rest of its pipeline.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
